Summary
Amgen Inc. (AMGN) filed an 8-K on September 17, 2010, reporting the issuance and sale of $1.5 billion in senior notes. Specifically, the company issued $900 million of 3.45% Senior Notes due 2020 and $600 million of 4.95% Senior Notes due 2041. The net proceeds from this offering, approximately $1.48 billion after expenses, are designated for general corporate purposes. These purposes include working capital, capital expenditures, debt service, share repurchases under existing programs, and strategic initiatives such as acquisitions and licensing. This move indicates Amgen's proactive approach to managing its capital structure and funding future growth opportunities. The new notes are senior unsecured debt and rank equally with other existing senior unsecured indebtedness of the company.
Key Highlights
- 1Amgen issued $900 million in 3.45% Senior Notes due 2020 and $600 million in 4.95% Senior Notes due 2041.
- 2Total aggregate principal amount of the notes issued is $1.5 billion.
- 3Net proceeds from the offering are approximately $1.48 billion after deducting discounts and expenses.
- 4Proceeds will be used for general corporate purposes, including working capital, capital expenditures, debt service, share repurchases, and strategic initiatives like acquisitions and licensing.
- 5The notes are senior unsecured indebtedness and rank equally with other existing senior unsecured debt.
- 6In the event of a change in control triggering event, noteholders have the option to require Amgen to repurchase their notes at 101% of the principal amount plus accrued interest.